S&P 500 falls as traders turn sour on tech
Investing.com - Leerink Partners raised its price target on Boston Scientific (NYSE:BSX) to $130.00 from $128.00 while maintaining an Outperform rating following the company’s third-quarter 2025 results. The company, currently valued at $154 billion, stands as a prominent player in the Healthcare Equipment & Supplies industry, with InvestingPro data showing an impressive "GREAT" overall financial health score.
Boston Scientific delivered strong third-quarter performance with worldwide sales exceeding consensus by 2%, including MedSurg sales 1% above expectations and Cardiovascular sales 2% above consensus. The company’s non-GAAP earnings per share came in 5% higher than analyst estimates. With trailing twelve-month revenue of $18.5 billion and robust revenue growth of 21.4%, the company continues to demonstrate solid operational execution.
The Watchman device was highlighted as a standout performer, surpassing consensus estimates by 6% and achieving 35% organic growth, significantly outpacing the company’s projected long-range plan of approximately 20% compound annual growth rate.
Boston Scientific’s newly issued guidance for the fourth quarter of 2025 sets both sales and earnings per share targets 2% above current consensus estimates.
Leerink cited several factors supporting its favorable outlook for Boston Scientific, including continued strength in pulsed field ablation (PFA), potential upside from Watchman sales following expected positive CHAMPION-AF results in the first half of 2026, increasing uptake of concomitant procedures, durable growth across the MedSurg portfolio, and margin improvements from favorable product mix and greater operating leverage.
In other recent news, Boston Scientific reported its third-quarter 2025 earnings, surpassing expectations with revenue reaching $5.07 billion, which is a 2.01% increase over forecasts. The company also posted adjusted earnings per share of $0.75, exceeding the consensus estimate of $0.71. This strong performance was supported by significant growth in operational sales and strategic product launches. Following these results, BTIG reiterated its Buy rating on the stock with a price target of $132.00. Evercore ISI also raised its price target to $113.00, maintaining an Outperform rating. Goldman Sachs increased its price target to $124.00, citing Boston Scientific’s strong positioning for sales and earnings growth. Similarly, Stifel reiterated its Buy rating with a $125.00 price target, expressing confidence in the company’s growth outlook. These developments highlight the positive sentiment among analysts regarding Boston Scientific’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.